Citadel Advisors’s Travere Therapeutics TVTX Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | $4.54M | Buy |
152,700
+114,400
| +299% | +$3.42M | ﹤0.01% | 4500 |
|
|
2025
Q4 | $1.46M | Sell |
38,300
-104,700
| -73% | -$3.4M | ﹤0.01% | 6563 |
|
|
2025
Q3 | $3.42M | Buy |
143,000
+33,800
| +31% | +$635K | ﹤0.01% | 5062 |
|
|
2025
Q2 | $1.62M | Buy |
109,200
+13,000
| +14% | +$215K | ﹤0.01% | 6120 |
|
|
2025
Q1 | $1.72M | Sell |
96,200
-33,700
| -26% | -$684K | ﹤0.01% | 5824 |
|
|
2024
Q4 | $2.26M | Sell |
129,900
-26,600
| -17% | -$470K | ﹤0.01% | 5372 |
|
|
2024
Q3 | $2.19M | Buy |
156,500
+98,100
| +168% | +$1.02M | ﹤0.01% | 5360 |
|
|
2024
Q2 | $480K | Sell |
58,400
-800
| -1% | -$5.39K | ﹤0.01% | 8136 |
|
|
2024
Q1 | $456K | Sell |
59,200
-20,200
| -25% | -$170K | ﹤0.01% | 8592 |
|
|
2023
Q4 | $714K | Buy |
79,400
+14,100
| +22% | +$103K | ﹤0.01% | 7356 |
|
|
2023
Q3 | $584K | Buy |
65,300
+57,800
| +771% | +$816K | ﹤0.01% | 7720 |
|
|
2023
Q2 | $115K | Sell |
7,500
-23,800
| -76% | -$433K | ﹤0.01% | 10719 |
|
|
2023
Q1 | $704K | Buy |
31,300
+30,000
| +2,308% | +$638K | ﹤0.01% | 7556 |
|
|
2022
Q4 | $27.3K | Buy |
+1,300
| New | +$27.5K | ﹤0.01% | 12844 |
|
|
2022
Q1 | – | Sell |
-54,000
| Closed | -$1.68M | – | 14601 |
|
|
2021
Q4 | $1.68M | Buy |
54,000
+5,800
| +12% | +$163K | ﹤0.01% | 6650 |
|
|
2021
Q3 | $1.17M | Sell |
48,200
-16,800
| -26% | -$309K | ﹤0.01% | 7755 |
|
|
2021
Q2 | $948K | Buy |
65,000
+8,300
| +15% | +$164K | ﹤0.01% | 8500 |
|
|
2021
Q1 | $1.42M | Buy |
56,700
+12,900
| +29% | +$356K | ﹤0.01% | 7241 |
|
|
2020
Q4 | $1.19M | Buy |
+43,800
| New | +$1.02M | ﹤0.01% | 6420 |
|
|
2019
Q4 | – | Sell |
-13,400
| Closed | -$155K | – | 9790 |
|
|
2019
Q3 | $155K | Sell |
13,400
-65,900
| -83% | -$1.09M | ﹤0.01% | 8284 |
|
|
2019
Q2 | $1.59M | Buy |
79,300
+69,500
| +709% | +$1.37M | ﹤0.01% | 4910 |
|
|
2019
Q1 | $222K | Sell |
9,800
-10,100
| -51% | -$223K | ﹤0.01% | 8069 |
|
|
2018
Q4 | $450K | Sell |
19,900
-8,000
| -29% | -$199K | ﹤0.01% | 6557 |
|
|
2018
Q3 | $802K | Buy |
+27,900
| New | +$798K | ﹤0.01% | 5928 |
|
|
2017
Q2 | – | Sell |
-15,100
| Closed | -$279K | – | 8082 |
|
|
2017
Q1 | $279K | Buy |
15,100
+3,200
| +27% | +$62.6K | ﹤0.01% | 5984 |
|
|
2016
Q4 | $225K | Sell |
11,900
-1,500
| -11% | -$30.7K | ﹤0.01% | 6127 |
|
|
2016
Q3 | $300K | Buy |
13,400
+1,900
| +17% | +$36.2K | ﹤0.01% | 5671 |
|
|
2016
Q2 | $205K | Sell |
11,500
-800
| -7% | -$12.9K | ﹤0.01% | 5800 |
|
|
2016
Q1 | $168K | Sell |
12,300
-18,300
| -60% | -$278K | ﹤0.01% | 5764 |
|
|
2015
Q4 | $590K | Buy |
30,600
+26,200
| +595% | +$523K | ﹤0.01% | 4250 |
|
|
2015
Q3 | $89K | Buy |
4,400
+1,800
| +69% | +$53.3K | ﹤0.01% | 7068 |
|
|
2015
Q2 | $86K | Sell |
2,600
-7,300
| -74% | -$200K | ﹤0.01% | 7235 |
|
|
2015
Q1 | $237K | Buy |
9,900
+6,500
| +191% | +$99.1K | ﹤0.01% | 5971 |
|
|
2014
Q4 | $42K | Sell |
3,400
-2,700
| -44% | -$27.9K | ﹤0.01% | 7327 |
|
|
2014
Q3 | $55K | Buy |
+6,100
| New | +$71.8K | ﹤0.01% | 6851 |
|
Other funds holding TVTX
AC
PA
VCM
NAMI
Citadel Advisors's TVTX Position: Q1 2026 in Review
Citadel Advisors increased its Travere Therapeutics (TVTX) stake by 531% in Q1 2026, buying an estimated $3.23M and bringing the position to 128,364 shares worth $3.81M. The position accounts for ﹤0.01% of the portfolio, ranked #4804.
Citadel Advisors first reported a position in TVTX in Q1 2014 and has held it in 47 quarters since. The position peaked at $37.1M in Q1 2022. 260 funds tracked by Wall St. Rank hold TVTX as of Q1 2026.
- Citadel Advisors held 128,364 shares of Travere Therapeutics worth $3.81M as of Q1 2026.
- Citadel Advisors bought 108,029 Travere Therapeutics shares in Q1 2026, an estimated $3.23M.
- Travere Therapeutics made up ﹤0.01% of Citadel Advisors's portfolio in Q1 2026, its #4804 holding.
- Citadel Advisors first reported a position in Travere Therapeutics in Q1 2014 and has held it in 47 quarters since.
- Citadel Advisors's Travere Therapeutics position peaked at $37.1M in Q1 2022.
- 260 funds tracked by Wall St. Rank held Travere Therapeutics as of Q1 2026.
Based on Citadel Advisors's 13F filing for Q1 2026, filed 15 May 2026.